Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXCEL: HaploNK for High-Risk AML
NCT04836390Phase 2Enrolling by invitation
- Start
- Aug 2021
- Primary completion
- May 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of haploidentical natural killer cells in acute myeloid leukemia (AML). Started Aug 2021; status: enrolling by invitation.
02
Drugs
haploidentical natural killer cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04836390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04836390.